

Dravet Syndrome Conference 2019

From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy

September 26th, 2019

Fundación ONCE

Calle Sebastián Herrera 15, 28012 Madrid




With the scientific endorsement of the Spanish Society of Neurology



SÍNDROME DE DRAVET
FUNDACIÓN

www.dravetfoundation.eu

INTRODUCTION



GENERAL OBJECTIVES – From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy

The theme of our 2019 conference is “From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy”.

This event is designed to bring together a range of professionals committed to improving the lives of people with epilepsy, including clinicians, researchers and professionals from the pharmaceutical industry.

There will be speaker presentations on the latest advances in epilepsy drug development using Dravet syndrome as an example of how the understanding and treatment of epilepsy has evolved and is constantly evolving over the years.

Presentations will include a variety of therapeutic modalities including small molecules, antisense oligonucleotides and gene therapy.

More information

Dravet Syndrome Foundation Spain was founded in 2011 by a group of parents with children affected by this rare disease, a group of impatient patients who do not resign themselves to the course of this disease. Our objective is to facilitate, foster and promote the development of research in the environment of Dravet syndrome in order to progress in the knowledge of its causes, improve its diagnosis and find effective treatments to mitigate and eliminate the adverse effects of this disease.



We encourage all stakeholders in health and medicines R&D to join this conference: policy makers, academics and researchers, pharmaceutical industry and other sectors in healthcare, SMEs and mid-sized enterprises, regulators, representatives of other public-private partnerships and research-funding organisations.

José Ángel Aibar. President, Dravet Syndrome Foundation Spain




With the scientific endorsement of the Spanish Society of Neurology



SÍNDROME DE DRAVET
FUNDACIÓN
www.dravetfoundation.eu

PROGRAM



09.00 – 09.30 Opening statements

09.30 – 09.45 Introduction to the program

09.45 – 10.30 Evolution in the diagnostic of rare genetic epilepsies

Moderator: Stephan Auvin, INSERM France

When Before genetics: clinical diagnosis of rare epilepsies

Rocío Sánchez Carpintero, Clínica Universidad de Navarra

The genetic revolution in rare epilepsies

Sara Álvarez, NIMGenetics

10.30 – 11.00 Coffee break

11.00 – 12.30 Treating seizures: symptomatic treatment of Dravet syndrome

Moderator: Antonio Gil-Nagel, Hospital Ruber Internacional

Treatment decisions in pharmaco-resistant epilepsy patients

Antonio Gil-Nagel, Hospital Ruber Internacional

The development of Epidiolex

Ángel Aledo, Hospital Ruber Internacional

The development of Fintepla

Stephan Auvin, INSERM France

The development of OV935

Juan Carlos Álvarez Sánchez, HU Virgen de las Nieves

12.30 – 13.30 Lunch break

13.30 – 15.10 Treating genes: disease-modifying treatment of Dravet syndrome

Moderator: Rubén Hernández, Cima Universidad de Navarra

Targeting Nav1.1-interneurons to restore cognitive and network functions

Jorge Palop, Gladstone Institutes

Gene therapy approaches for Dravet Syndrome

Rajvinder Karda, University College of London

Delivery of the entire SCN1A coding sequence using High-Capacity Adenoviral vectors for the treatment of Dravet syndrome

Ana Ricobaraza, Cima Universidad de Navarra

Restoring gene expression with gene therapy

Jen Seda, Encoded Therapeutics

TANGO technology and its application to Dravet Syndrome: a novel approach to the cause of the disease

Javier Avendaño, Stoke Therapeutics

15.10 – 15.30 Coffee Break

15.30 – 15.50 Patient organizations as partners in drug development


15.50 – 16.30 Open discussions and closure

Organised by:

FUNDACIÓN SÍNDROME DE DRAVET

informacion@dravetfoundation.eu

www.dravetfoundation.eu



Sponsored by:

ZOGENIX

GW
pharmaceuticals

Ovid
THERAPEUTICS

innomedix
Knowledge in action


Facilities provided at no cost by:

Fundación ONCE – C/Sebastián Herrera 15, 28012 Madrid



With the scientific endorsement of the Spanish Society of Neurology


SÍNDROME DE DRAVET
FUNDACIÓN
www.dravetfoundation.eu



Dravet Syndrome Conference 2019

From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy

September 26th, 2019

Fundación ONCE

Sebastián Herrera 15, 28012 Madrid



With the scientific endorsement of the Spanish Society of Neurology



SÍNDROME DE DRAVET
FUNDACIÓN

www.dravetfoundation.eu